EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Medical therapy after surgical aortic valve replacement for aortic regurgitation

Charlotta Törngren, Kristjan Jonsson iD, Emma C Hansson, Amar Taha, Anders Jeppsson iD, Andreas Martinsson iD

European Journal of Cardio-Thoracic Surgery · 2023

DOI: 10.1093/ejcts/ezad042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2023. Verfasst von Charlotta Törngren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Aortic Valve Insufficiency, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypertension, Aortic Valve Stenosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish Heart-Lung Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES Current clinical guidelines have no specific recommendations regarding medical therapy after surgical aortic valve replacement in patients with aortic regurgitation (AR). We studied the association between medical therapy with renin–angiotensin system (RAS) inhibitors, statins and β-blockers and long-term major adverse cardiovascular events. METHODS All patients undergoing valve replacement due to AR between 2006 and 2017 in Sweden and alive 6 months after discharge were included. Time-dependent multivariable Cox regression models adjusted for age, sex, patient characteristics, comorbidities, other medications and year of surgical aortic valve replacement were used. Primary outcome was a composite of all-cause mortality, myocardial infarction and stroke. Subgroup analyses based on age, sex, heart failure, low ejection fraction, hyperlipidaemia and hypertension were performed. RESULTS A total of 2204 patients were included [median follow-up 5.0 years (range 0.0–11.5)]. At baseline, 68% of the patients were dispensed RAS inhibitors, 80% β-blockers and 35% statins. Dispense of RAS inhibitors and β-blockers declined over time, especially during the first year after baseline, while dispense of statins remained stable. Treatment with RAS inhibitors or statins was associated with a reduced risk of the primary outcome [adjusted hazard ratio (aHR) 0.71, 95% confidence interval (CI) 0.57–0.87 and aHR 0.78, 95% CI 0.62–0.99, respectively]. The results were consistent in subgroups based on age, sex and comorbidities. β-Blocker treatment was associated with an increased risk for the primary outcome (aHR 1.35, 95% CI 1.07–1.70). CONCLUSIONS The results indicate a potential beneficial association of RAS inhibitors and statins as part of a secondary preventive treatment regime after aortic valve replacement in patients with AR. The role of β-blockers needs to be further investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve InsufficiencyHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionAortic Valve StenosisTranscatheter Aortic Valve ReplacementHumansAortic ValveAngiotensin-Converting Enzyme InhibitorsTreatment OutcomeRisk Factors

Stichwörter der Autor:innen

Aortic regurgitationMedical therapyRenin–angiotensin system inhibitorsStatinssurgical aortic valve replacementβ-Blockers

Substanzen

Angiotensin-Converting Enzyme InhibitorsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

ORCID-Profile: Kristjan Jonsson, Anders Jeppsson, Andreas Martinsson

Förderung

  • Swedish Heart-Lung Foundation

Zitieren

APA

Törngren, C., Jonsson, K., Hansson, E. C., Taha, A., Jeppsson, A., & Martinsson, A. (2023). Medical therapy after surgical aortic valve replacement for aortic regurgitation. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezad042

Vancouver

Törngren C, Jonsson K, Hansson EC, Taha A, Jeppsson A, Martinsson A. Medical therapy after surgical aortic valve replacement for aortic regurgitation. European Journal of Cardio-Thoracic Surgery. 2023. doi:10.1093/ejcts/ezad042

BibTeX
@article{Trngren2023,
  author = {Törngren, Charlotta and Jonsson, Kristjan and Hansson, Emma C and Taha, Amar and Jeppsson, Anders and Martinsson, Andreas},
  title = {Medical therapy after surgical aortic valve replacement for aortic regurgitation},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2023},
  doi = {10.1093/ejcts/ezad042}
}
Kostenlos starten →